Tags

Type your tag names separated by a space and hit enter

Medical treatment of Zollinger-Ellison syndrome with ranitidine.
Int J Tissue React. 1983; 5(4):339-43.IJ

Abstract

Ten patients with Zollinger-Ellison syndrome (4 with intact stomach and 6 with previous partial gastrectomy) received ranitidine (600-1200 mg daily) for 2-24 months (mean 14 months). The inhibitory effect of ranitidine on acid secretion was evaluated by measuring acid output during the third hour following a single drug administration in all cases, and by the 24-hour intragastric pH profile in 5 patients. Therapeutic efficacy was assessed by clinical and endoscopic criteria. Ranitidine at different dosages, related to the rate of acid secretion, was effective in controlling peptic disease and diarrhoea in the majority of patients. The secretory parameters used in this study allowed evaluation of the inhibitory effect of ranitidine on acid secretion, in order to select the best therapeutic dose and to decide on surgical cure in the patients non-responsive even to the highest dosage.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6323334

Citation

Vezzadini, P, et al. "Medical Treatment of Zollinger-Ellison Syndrome With Ranitidine." International Journal of Tissue Reactions, vol. 5, no. 4, 1983, pp. 339-43.
Vezzadini P, Bonora G, Tomassetti P, et al. Medical treatment of Zollinger-Ellison syndrome with ranitidine. Int J Tissue React. 1983;5(4):339-43.
Vezzadini, P., Bonora, G., Tomassetti, P., Pazzaglia, M., & Labò, G. (1983). Medical treatment of Zollinger-Ellison syndrome with ranitidine. International Journal of Tissue Reactions, 5(4), 339-43.
Vezzadini P, et al. Medical Treatment of Zollinger-Ellison Syndrome With Ranitidine. Int J Tissue React. 1983;5(4):339-43. PubMed PMID: 6323334.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medical treatment of Zollinger-Ellison syndrome with ranitidine. AU - Vezzadini,P, AU - Bonora,G, AU - Tomassetti,P, AU - Pazzaglia,M, AU - Labò,G, PY - 1983/1/1/pubmed PY - 1983/1/1/medline PY - 1983/1/1/entrez SP - 339 EP - 43 JF - International journal of tissue reactions JO - Int J Tissue React VL - 5 IS - 4 N2 - Ten patients with Zollinger-Ellison syndrome (4 with intact stomach and 6 with previous partial gastrectomy) received ranitidine (600-1200 mg daily) for 2-24 months (mean 14 months). The inhibitory effect of ranitidine on acid secretion was evaluated by measuring acid output during the third hour following a single drug administration in all cases, and by the 24-hour intragastric pH profile in 5 patients. Therapeutic efficacy was assessed by clinical and endoscopic criteria. Ranitidine at different dosages, related to the rate of acid secretion, was effective in controlling peptic disease and diarrhoea in the majority of patients. The secretory parameters used in this study allowed evaluation of the inhibitory effect of ranitidine on acid secretion, in order to select the best therapeutic dose and to decide on surgical cure in the patients non-responsive even to the highest dosage. SN - 0250-0868 UR - https://www.unboundmedicine.com/medline/citation/6323334/Medical_treatment_of_Zollinger_Ellison_syndrome_with_ranitidine_ L2 - http://www.diseaseinfosearch.org/result/7600 DB - PRIME DP - Unbound Medicine ER -